Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers

Prostate

Volumn 74, Issue 16, 2014, Pages 1647-1654

  Fleischmann, Achim ^a   Saramäki, Outi R ^b   Zlobec, Inti ^a   Rotzer, Diana ^a   Genitsch, Vera ^a   Seiler, Roland ^c   Visakorpi, Tapio ^b,d   Thalmann, George N ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF BERN   (Switzerland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

metastases; prostate cancer; survival; TMPRSS2 ERG

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE SPECIFIC SURVIVAL; ERG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FUSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TISSUE MICROARRAY; TMPRSS2 GENE; COHORT ANALYSIS; FOLLOW UP; GENETICS; GENOTYPE; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREVALENCE; PROGNOSIS; PROSTATE TUMOR; RETROSPECTIVE STUDY; SURVIVAL RATE;

ERG PROTEIN, HUMAN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

AGED; COHORT STUDIES; FOLLOW-UP STUDIES; GENE FUSION; GENOTYPE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS;

EID: 84921984191     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22882     Document Type: Article

References (30)

1. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
2. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA,. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 2009; 56: 275-286.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
4. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA,. TMPRSS2: ERG fusion- associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-8341.
5. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA,. ERG Rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010; 75: 762-767.
6. Guo CC, Wang Y, Xiao L, Troncoso P, Czerniak BA,. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol 2012; 43: 644-649.
7. Bader P, Burkhard FC, Markwalder R, Studer UE,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure ? J Urol 2003; 169: 849-854.
8. Fleischmann A, Schobinger S, Markwalder R, Schumacher M, Burkhard F, Thalmann GN, Studer UE,. Prognostic factors in lymph node metastases of prostatic cancer patients: The size of the metastases but not extranodal extension independently predicts survival. Histopathology 2008; 53: 468-475.
9. Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE,. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 2009; 69: 352-362.
10. Sakr WA, Grignon DJ, Visscher DW, Wolman SR, Crissman JD,. Evaluating the radical prostatectomy specimen, part I. J Urol Pathol 1995; 3: 355-364.
11. Sobin LH, Wittekind C, Gospodarowicz MK,. (eds.). TNM Atlas. 7th Edition. Oxfort: Wiley-Blackwell; 2009.
12. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB,. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-7995.
13. Wise AM, Stamey TA, McNeal JE, Clayton JL,. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264-269.
14. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T,. TMPRS S2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-3400.
15. Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN,. High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Arch 2011; 458: 741-748.
16. Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN,. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology 2011; 58: 781-789.
17. Fleischmann A, Rocha C, Schobinger S, Seiler R, Wiese B, Thalmann GN,. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate 2011; 71: 453-460.
18. Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F, Perner S,. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011; 58: 1028-1036.
19. Xiao L, Zhu XZ, Wang Y, Gong Y, Guo CC,. TMPRSS2-ERG gene fusion in metastatic prostate cancers: A study of fine needle aspiration specimens. Zhonghua Bing Li Xue Za Zhi 2011; 40: 392-396.
20. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584-3590.
21. Barry M, Perner S, Demichelis F, Rubin MA,. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 2007; 70: 630-633.
22. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA,. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21: 67-75.
23. Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ,. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy. BJU International 2011; 108: 1074-1085.
24. Andreoiu M, Cheng L,. Multifocal prostate cancer: Biologic, prognostic, and therapeutic implications. Hum Pathol 2010; 41: 781-793.
25. Ruijter ET, Van De Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ,. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996; 180: 295-299.
26. Minner S, Gärtner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C, Simon R, Sauter G, Schlomm T, Wilczak W,. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol 2013; 26: 106-116.
27. Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, Satagopan JM, Scardino PT, Gerald WL, Reuter VE,. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010; 23: 1325-1333.
28. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA,. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451-1460.
29. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL,. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-1406.
30. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T,. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 5878-5888.